You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Natalizumab

Showing 1 - 25 of 164
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis Trial (Natalizumab)

Not yet recruiting
  • Multiple Sclerosis
  • Natalizumab
  • (no location specified)
Jun 21, 2023

End of Dose Phenomena in Subcutaneous Natalizumab Treated

Not yet recruiting
  • Multiple Sclerosis
  • Natalizumab
  • (no location specified)
Jan 18, 2023

Multiple Sclerosis Trial in Clermont-Ferrand (Methylprednisolone, Placebo, natalizumab (NTZ))

Recruiting
  • Multiple Sclerosis
  • Clermont-Ferrand, France
    CHU Clermont-Ferrand
Jan 5, 2023

Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination Trial (Tysabri Injectable Product, Placebo)

Recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome of Demyelination
  • Tysabri Injectable Product
  • Placebo
  • London, United Kingdom
    Royal London Hospital
Jan 25, 2023

Sickle Cell Disease Trial in Saint Louis (Motixafortide, Natalizumab, Leukapheresis)

Not yet recruiting
  • Sickle Cell Disease
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 8, 2022

MS Had Greater Than 60 Infusions of Natalizumab

Active, not recruiting
  • Multiple Sclerosis
  • Natalizumab
  • Latham, New York
    Multiple Sclerosis Center of Northeastern New York, P.C.
Mar 23, 2022

Relapsing-remitting Multiple Sclerosis (RRMS) Trial in New York (BeCare application)

Recruiting
  • Relapsing-remitting Multiple Sclerosis (RRMS)
  • BeCare application
  • New York, New York
    Mount Sinai Hospital
Dec 13, 2021

Multiple Sclerosis Trial in Nashville (Natalizumab 300 MG in 15 ML Injection)

Recruiting
  • Multiple Sclerosis
  • Natalizumab 300 MG in 15 ML Injection
  • Nashville, Tennessee
    Vanderbilt University Medical Center
Jan 8, 2022

The 'Wearing Off' Effect of DMT

Recruiting
  • Multiple Sclerosis
  • ocrelizumab
  • +2 more
  • Basel, Switzerland
    Novartis Investigative Site
Jan 24, 2023

Natalizumab Extended Interval Dosing in a French Cohort

Completed
  • Multiple Sclerosis, Relapsing-Remitting
  • Natalizumab Injection [Tysabri]
  • Bobigny, France
  • +4 more
Mar 8, 2022

Schizophrenia Trial in London (Natalizumab, Placebo: normal saline)

Recruiting
  • Schizophrenia
  • Natalizumab
  • Placebo: normal saline
  • London, United Kingdom
    Institute of Psychiatry, Psychology and Neuroscience, King's Col
Sep 27, 2022

Multiple Sclerosis Trial (Diroximel Fumarate, Avonex, Tysabri)

Not yet recruiting
  • Multiple Sclerosis
  • Diroximel Fumarate
  • +3 more
  • (no location specified)
Dec 12, 2022

Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
  • Multiple Sclerosis
  • interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
  • Prague, Czechia
    IMPULS Endowment Fund
Mar 7, 2023

Multiple Sclerosis (MS) Trial in Dallas (Alemtuzumab)

Completed
Has Results
  • Multiple Sclerosis (MS)
  • Dallas, Texas
  • +1 more
Jan 24, 2022

Multiple Sclerosis Trial in Czechia (Natalizumab)

Recruiting
  • Multiple Sclerosis
  • Natalizumab
  • Brno, Czechia
  • +14 more
Feb 2, 2022

Transitioning Patients From Natalizumab to Ocrelizumab

Completed
  • Relapsing Remitting Multiple Sclerosis
    • Livingston, New Jersey
    • +4 more
    Feb 2, 2022

    Benefit of Natalizumab At-home Infusion vs At-hospital Infusion

    Recruiting
    • Multiple Sclerosis (MS)
    • At-home natalizumab treated MS patient
    • Strasbourg, Bas-Rhin, France
    • +19 more
    Mar 22, 2022

    Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

    Recruiting
    • Multiple Sclerosis
    • Diroximel Fumarate
    • +8 more
    • Eden Prairie, Minnesota
      OptumInsight
    Jan 9, 2023

    Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in West Hollywood (Dosing Interruption of Natalizumab)

    Recruiting
    • Multiple Sclerosis
    • Multiple Sclerosis, Relapsing-Remitting
    • Dosing Interruption of Natalizumab
    • West Hollywood, California
      Regina Berkovich MD, PhD Inc.
    Jul 20, 2021

    Relapsing Remitting Multiple Sclerosis Trial in Netherlands (Personalized extended interval dosing of natalizumab, Standard

    Recruiting
    • Relapsing Remitting Multiple Sclerosis
    • Personalized extended interval dosing of natalizumab
    • Standard interval dosing
    • Almelo, Netherlands
    • +23 more
    Sep 22, 2021

    Acute GVHD Trial in United States (natalizumab, steroids)

    Active, not recruiting
    • Acute Graft Versus Host Disease
    • Duarte, California
    • +11 more
    Oct 15, 2021

    Safety of Exposure to Natalizumab During Pregnancy

    Recruiting
    • Multiple Sclerosis
    • Questionnaire
    • Besançon, France
    • +26 more
    Jun 27, 2022

    Epilepsy, Focal Seizures, Partial Seizures Trial in United States (Natalizumab, Placebo)

    Completed
    Has Results
    • Epilepsy, Focal Seizures, Partial Seizures
    • Natalizumab
    • Placebo
    • Birmingham, Alabama
    • +30 more
    Nov 17, 2021

    Relapsing-remitting Multiple Sclerosis Trial in Stockholm (Rituximab)

    Active, not recruiting
    • Relapsing-remitting Multiple Sclerosis
    • Stockholm, Sweden
      Fredrik Piehl
    Apr 8, 2022

    Multiple Sclerosis (MS) Registries

    Active, not recruiting
    • Progressive Multifocal Leukoencephalopathy
    • Tysabri
    • Cambridge, Massachusetts
      Research Site
    Mar 21, 2022